69 related articles for article (PubMed ID: 25624151)
1. Factors affecting ¹⁸F FDOPA standardized uptake value in patients with primary brain tumors after treatment.
Chiaravalloti A; Fiorentini A; Villani V; Carapella C; Pace A; Di Pietro B; Di Russo C; Palumbo B; Floris R; Schillaci O
Nucl Med Biol; 2015 Apr; 42(4):355-9. PubMed ID: 25624151
[TBL] [Abstract][Full Text] [Related]
2. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.
Fueger BJ; Czernin J; Cloughesy T; Silverman DH; Geist CL; Walter MA; Schiepers C; Nghiemphu P; Lai A; Phelps ME; Chen W
J Nucl Med; 2010 Oct; 51(10):1532-8. PubMed ID: 20847166
[TBL] [Abstract][Full Text] [Related]
3. Overall survival and progression-free survival in patients with primary brain tumors after treatment: is the outcome of [
Chiaravalloti A; Esposito V; Ursini F; Di Giorgio E; Zinzi M; Calabria F; Cimini A; Schillaci O
Ann Nucl Med; 2019 Jul; 33(7):471-480. PubMed ID: 30949937
[TBL] [Abstract][Full Text] [Related]
4. IDH mutation is paradoxically associated with higher
Verger A; Metellus P; Sala Q; Colin C; Bialecki E; Taieb D; Chinot O; Figarella-Branger D; Guedj E
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1306-1311. PubMed ID: 28293705
[TBL] [Abstract][Full Text] [Related]
5. (18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment.
Lizarraga KJ; Allen-Auerbach M; Czernin J; DeSalles AA; Yong WH; Phelps ME; Chen W
J Nucl Med; 2014 Jan; 55(1):30-6. PubMed ID: 24167081
[TBL] [Abstract][Full Text] [Related]
6. Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas.
Tripathi M; Sharma R; D'Souza M; Jaimini A; Panwar P; Varshney R; Datta A; Kumar N; Garg G; Singh D; Grover RK; Mishra AK; Mondal A
Clin Nucl Med; 2009 Dec; 34(12):878-83. PubMed ID: 20139821
[TBL] [Abstract][Full Text] [Related]
7. Can (18)F-FDOPA PET/CT predict survival in patients with suspected recurrent glioma? A prospective study.
Karunanithi S; Sharma P; Kumar A; Gupta DK; Khangembam BC; Ballal S; Kumar R; Kumar R; Bal C
Eur J Radiol; 2014 Jan; 83(1):219-25. PubMed ID: 24191944
[TBL] [Abstract][Full Text] [Related]
8. Prospective comparison of (99m)Tc-GH SPECT/CT and (18)F-FDOPA PET/CT for detection of recurrent glioma: a pilot study.
Karunanithi S; Bandopadhyaya GP; Sharma P; Kumar A; Singla S; Malhotra A; Gupta DK; Bal C
Clin Nucl Med; 2014 Feb; 39(2):e121-8. PubMed ID: 23579970
[TBL] [Abstract][Full Text] [Related]
9. 18F-FDOPA kinetics in brain tumors.
Schiepers C; Chen W; Cloughesy T; Dahlbom M; Huang SC
J Nucl Med; 2007 Oct; 48(10):1651-61. PubMed ID: 17873130
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience.
Ledezma CJ; Chen W; Sai V; Freitas B; Cloughesy T; Czernin J; Pope W
Eur J Radiol; 2009 Aug; 71(2):242-8. PubMed ID: 18511228
[TBL] [Abstract][Full Text] [Related]
11. Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy.
Schwarzenberg J; Czernin J; Cloughesy TF; Ellingson BM; Pope WB; Grogan T; Elashoff D; Geist C; Silverman DH; Phelps ME; Chen W
Clin Cancer Res; 2014 Jul; 20(13):3550-9. PubMed ID: 24687922
[TBL] [Abstract][Full Text] [Related]
12. A high
Isal S; Gauchotte G; Rech F; Blonski M; Planel S; Chawki MB; Karcher G; Marie PY; Taillandier L; Verger A
Br J Radiol; 2018 Apr; 91(1084):20170803. PubMed ID: 29271237
[TBL] [Abstract][Full Text] [Related]
13. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas.
Imani F; Agopian VG; Auerbach MS; Walter MA; Imani F; Benz MR; Dumont RA; Lai CK; Czernin JG; Yeh MW
J Nucl Med; 2009 Apr; 50(4):513-9. PubMed ID: 19289420
[TBL] [Abstract][Full Text] [Related]
14. Rate of change in maximum
Oughourlian TC; Yao J; Schlossman J; Raymond C; Ji M; Tatekawa H; Salamon N; Pope WB; Czernin J; Nghiemphu PL; Lai A; Cloughesy TF; Ellingson BM
J Neurooncol; 2020 Mar; 147(1):135-145. PubMed ID: 31981013
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of quantitative criteria for glioma grading with static and dynamic 18F-FDopa PET/CT.
Nioche C; Soret M; Gontier E; Lahutte M; Dutertre G; Dulou R; Capelle L; Guillevin R; Foehrenbach H; Buvat I
Clin Nucl Med; 2013 Feb; 38(2):81-7. PubMed ID: 23334119
[TBL] [Abstract][Full Text] [Related]
16. Head-to-head comparison between
Heimburger C; Veillon F; Taïeb D; Goichot B; Riehm S; Petit-Thomas J; Averous G; Cavalcanti M; Hubelé F; Chabrier G; Namer IJ; Charpiot A; Imperiale A
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):979-987. PubMed ID: 28050631
[TBL] [Abstract][Full Text] [Related]
17. Estimation of patient dose in (18)F-FDG and (18)F-FDOPA PET/CT examinations.
Kaushik A; Jaimini A; Tripathi M; D'Souza M; Sharma R; Mishra AK; Mondal A; Dwarakanath BS
J Cancer Res Ther; 2013; 9(3):477-83. PubMed ID: 24125986
[TBL] [Abstract][Full Text] [Related]
18. Characterization of neuroblastic tumors using 18F-FDOPA PET.
Lu MY; Liu YL; Chang HH; Jou ST; Yang YL; Lin KH; Lin DT; Lee YL; Lee H; Wu PY; Luo TY; Shen LH; Huang SF; Liao YF; Hsu WM; Tzen KY;
J Nucl Med; 2013 Jan; 54(1):42-9. PubMed ID: 23213196
[TBL] [Abstract][Full Text] [Related]
19. The Role of PET [18F]FDOPA in Evaluating Low-grade Glioma.
Villani V; Carapella CM; Chiaravalloti A; Terrenato I; Piludu F; Vidiri A; Schillaci O; Floris R; Marzi S; Fabi A; Pace A
Anticancer Res; 2015 Sep; 35(9):5117-22. PubMed ID: 26254416
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDOPA: a multiple-target molecule.
Minn H; Kauhanen S; Seppänen M; Nuutila P
J Nucl Med; 2009 Dec; 50(12):1915-8. PubMed ID: 19910423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
